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IN VIVO EXPERIMENTS WITH A MOUSE MODEL FOR β-THALASSEMIA
β-thalassemia disease is a highly prevalent hereditary type of anemia caused by the absence or reduction in β-globin chain synthesis, one of the subunits of adult hemoglobin (HbA), mainly due
to very heterogeneous mutations in the β-globin gene. The basis of β-thalassemia lies in the fact that HbA cannot be formed because of this lack. Free α-globin chains then accumulate in red
blood cells (RBC) and their precursors, causing their apoptosis, peripheral hemolysis, and ineffective erythropoiesis. The result of both events is chronic-hemolytic anemia, which leads to
extramedullary hematopoiesis, iron overload, and many other adverse events such as organ systems impairment (Figure 1).
A  C O M B I N E D  G E N E  T H E R A P Y  S T R A T E G Y  F O R
β - T H A L A S S E M I A  T R E A T M E N T
A  r e s e a r c h  p r o j e c t  p r o p o s a l
1) Design a lentiviral vector that includes the β-globin gene and an shRNA targeting BCL11A.
2) Prove if the vector increases the total Hb content and reduces free α-globin in RBC from
β-thalassemia patients comparing to previous successful therapies. 
3) Test if the above results can be obtained in vivo in a mouse model of β-thalassemia and if
treatment with the new vector ameliorates the symptomatology of the disease.
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Table 1. Current treatments of β-thalassemia and their main disadvantages.
Figure 1. Main mechanisms in the pathophysiology of β-thalassemia.
Adapted from Mettananda, S. et al. (2016).
The simultaneous addition of the β-globin gene and inhibition of BCL11A in β-thalassemic
HSCs significantly reduces α/non-α globin chain imbalance in erythroid cells. Consequently,
this also leads to an improvement in the symptomatology of the disease comparing to
previous successful gene therapies.
LENTIVIRAL VECTOR DESIGN AND PRODUCTION IN VITRO EXPERIMENTS WITH β-THALASSEMIC HSCs
In vitro results: It is expected to see β- and γ-globin chains, HbA, and fetal Hb synthesis, in addition to the highest total Hb concentration, in erythroid cells from β-thalassemia patients treated
with the new vector. Furthermore, a peak seen in untreated cells corresponding to α-globin chain aggregates should disappear in the study group of cells. 
In vivo results: Regarding globin chains and Hb concentration, it is expected to see the same pattern of results as in vitro studies, considering that, in this case, mouse embryonic globin is
produced instead of γ-globin. Moreover, liver and spleen histology in treated mice should show average weight, normal tissue characteristics, and few iron depositions, indicating a reduction in
anemia, extramedullary erythropoiesis, and splenomegaly.
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Figure 2. Vector diagram and
production procedure. The
design is based on the
previously proven successful
LentiGlobin BB305 lentiviral
vector and an shRNAmiR vector. Figure 3. Design of the general steps of in vitro assays.
Figure 4. Design of the general procedure
followed with β-thalassemic mice in the in
vivo assays.
There are several ways to treat β-thalassemia. However, these therapies still have some
drawbacks (Table 1). What is proposed here is to combine the addition of the β-globin gene and
the induction of γ-globin expression. The latter can take place by repressing BCL11A, a
transcription factor that has been validated as an essential element in γ-globin silencing. This way,
an improvement in current therapies can be achieved as it may give less likelihood of manifesting
problems associated with NTDT.
